PwPepwise

N-Acetyl Semax Amidate

Brain & Focus

a.k.a. NA Semax

Stabilized Semax variant

N-Acetyl Semax Amidate is an enhanced synthetic derivative of Semax, itself a peptide analogue of a fragment of adrenocorticotropic hormone (ACTH).

§01Summary

N-Acetyl Semax Amidate is an enhanced synthetic derivative of Semax, itself a peptide analogue of a fragment of adrenocorticotropic hormone (ACTH). The acetylated and amidated modifications are designed to improve the compound's stability and its ability to cross biological membranes, including the blood-brain barrier, making it a more potent and longer-acting form compared to standard Semax. It is primarily investigated for its nootropic and neuroprotective properties, meaning it may support cognitive function, memory, and the health of nerve cells.

Research into the Semax family of peptides has explored potential applications in neurological conditions, including stroke recovery and neurodegenerative diseases. Preliminary preclinical evidence suggests N-Acetyl Semax Amidate may influence the expression of neurotrophic factors — proteins that support the survival and growth of neurons. The broader Semax compound has been studied in the context of Parkinson's disease-related pathways, where synthetic peptides in this class appear to modulate genes involved in neuronal support. The evidence base for this specific modified form is actively developing, and human studies are emerging to characterize its full therapeutic profile.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

N-Acetyl Semax Amidate is a chemically modified analogue of Semax, which is itself derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH(4-10)). The parent Semax sequence is Met-Glu-His-Phe-Pro-Gly-Pro; N-Acetyl Semax Amidate incorporates an N-terminal acetyl group and a C-terminal amide group. These modifications serve distinct pharmacological purposes: N-terminal acetylation protects the peptide from aminopeptidase-mediated degradation, while C-terminal amidation prevents carboxypeptidase cleavage and mimics the structural motif of many endogenous bioactive peptides that naturally terminate in an amide. Together, these changes are expected to substantially extend plasma and tissue half-life relative to unmodified Semax.

The Semax peptide family is understood to exert its primary effects through modulation of neurotrophic factor systems, most notably brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Related peptides in this class have been investigated for their capacity to influence Gdnf gene expression and the expression of its cognate receptors in dopaminergic pathways, findings relevant to neuroprotective mechanisms in models of Parkinson's disease. These neurotrophic interactions are thought to support neuronal survival, synaptic plasticity, and potentially dopaminergic system integrity.

At the receptor level, Semax-family peptides are reported to interact with melanocortin receptors, particularly MC4R and MC5R, which are expressed in the central nervous system and are implicated in cognitive modulation, neuroprotection, and anti-inflammatory signaling. Downstream effects may include activation of the MAPK/ERK pathway and modulation of cAMP-dependent signaling cascades, contributing to synaptic strengthening and neuronal resilience. The acetylated and amidated form is hypothesized to engage these targets with greater affinity and duration than the parent compound due to its enhanced proteolytic stability.

Pharmacokinetically, intranasal administration is the primary delivery route studied for Semax-family peptides, leveraging direct olfactory and trigeminal pathways to achieve central nervous system delivery while bypassing first-pass hepatic metabolism. The enhanced chemical stability conferred by the dual modifications of N-Acetyl Semax Amidate suggests improved bioavailability and prolonged receptor engagement, though formal pharmacokinetic parameters — including precise half-life, volume of distribution, and metabolite profiles — for this specific derivative are an area of continuing investigation.

§04Evidence & efficacy

Evidence base
2Studies
0Human
0Animal

The analyzed dataset does not contain direct efficacy evidence for N-Acetyl Semax Amidate. One study examined the effect of synthetic peptides in the broader Semax family on the expression of Gdnf and its receptors in a rat model of 6-OHDA-induced Parkinson's-like pathology, suggesting that related peptides may influence neurotrophic signaling pathways relevant to neuroprotection. A second record reviewed the Semax drug class in the context of stroke pharmacotherapy. Neither study provided outcome data, effect sizes, or controlled efficacy measurements attributable to the N-Acetyl Semax Amidate form specifically. Efficacy characterization for this derivative is an area of active research.

§05Safety

No safety data for N-Acetyl Semax Amidate was captured in the analyzed studies, as both records were filtered for low relevance and contained no adverse event, tolerability, or contraindication information. The broader Semax peptide family has generally been regarded as well-tolerated in the research literature, and intranasal administration routes used for related compounds are associated with local tolerability, but these observations cannot be directly attributed to the acetylated and amidated form without dedicated safety studies. Human safety characterization for this specific derivative is an active area of clinical investigation.

§06History

The Semax peptide was originally developed in the Soviet Union and subsequently Russia, emerging from research programs at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The foundational work focused on identifying biologically active fragments of ACTH that retained neuroprotective and cognitive-enhancing properties without the hormonal activity of the full 39-amino-acid parent hormone. Semax (ACTH 4-10 analogue with a Pro-Gly-Pro C-terminal extension) was granted regulatory approval in Russia by the 1990s for indications including stroke, transient ischemic attack, and cognitive impairment, and is marketed as Semax® under oversight from Russian regulatory authorities.

N-Acetyl Semax Amidate represents a later-generation structural refinement, developed to improve upon the metabolic stability and potency of the original compound through dual terminal modifications. This derivative emerged as part of broader medicinal chemistry efforts to optimize peptide therapeutics for central nervous system applications. Research into the Semax family's effects on neurotrophic factor expression, including GDNF pathway modulation in Parkinson's disease models, has been explored in preclinical settings in the 2010s. The compound has attracted interest in research communities studying nootropics and neuroprotection, and its evidence base is actively developing across multiple investigational contexts.

§07References